Quantcast
Last updated on April 18, 2014 at 7:29 EDT

Latest Oncolytic virus Stories

2010-04-14 06:30:00

CALGARY, April 14 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that abstracts covering both clinical and preclinical research with reovirus (REOLYSIN(R)) are available on the American Association for Cancer Research (AACR) website at www.aacr.org, and on the Oncolytics website at www.oncolyticsbiotech.com. The research is scheduled to be delivered at the 101st AACR Annual Meeting in Washington, DC, April 17-21, 2010. "Our preclinical...

2010-04-13 08:00:00

SAN FRANCISCO, April 13 /PRNewswire/ -- Jennerex, Inc. (San Francisco, CA and Ottawa, Ontario), a clinical-stage cancer biotherapeutics company, today announced that it has completed patient enrollment in a Phase 1 clinical trial evaluating the intravenous (IV) administration of JX-594, the company's lead product for the treatment of solid tumors. Jennerex expects to report the results from this trial at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in May 2010....

2010-04-08 06:30:00

CALGARY, April 8 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that a paper entitled "Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice," co-senior authored by Dr. Richard Vile of the Department of Immunology, Mayo Clinic, Rochester, Minnesota, USA, and Dr. Kevin Harrington of the Institute of Cancer Research, London, UK, was published in the online version of the Journal...

2010-04-02 12:26:38

For several years, researchers have been developing a new approach to treating cancer that uses viruses to infect and kill cancer cells while leaving normal cells unharmed. Recent data have indicated that this approach, which is known as oncolytic virotherapy, has potential. Now, Richard Vile and colleagues, at the Mayo Clinic, Rochester, have found that this approach can be combined with a standard clinical therapy to provide substantial regression and cure of tumors in mice, leading them to...

2010-03-09 13:30:55

Researchers in Canada have detected a novel oncolytic viral therapy against prostate cancer with use of a virus called the reovirus, according to study results published in Cancer Research, a journal of the American Association for Cancer Research. The respiratory, enteric, orphan virus (commonly known as reovirus) is a non-attenuated, environmental virus that has shown oncolytic potential against many types of cancer, specifically lymphoid, ovarian, breast, pancreatic and high grade glioma...

2010-01-27 08:00:00

LAKE FOREST, Calif., Jan. 27 /PRNewswire/ -- New Medicine's Oncology KnowledgeBASE (nm/OK) residing at http://nmok.net became available on the Internet 10 years ago and, since then, the oncology field has evolved into one of the most challenging, complex and promising drug development sectors, both in terms of its potential contribution to medicine and to its market opportunities. The global market of oncology drugs is forecast to reach $80 billion by the middle of this decade, more that...

2009-12-23 08:00:00

SAN FRANCISCO, Dec. 23 /PRNewswire/ -- Jennerex Biotherapeutics, a clinical-stage biotherapeutics company developing a proprietary breakthrough class of targeted oncolytic virus therapeutics, today announced that management will present at the following upcoming investor conferences. Biotech Showcase 2010 Tuesday, January 12, 2010 9:40 a.m. PT Marines' Memorial Club and Hotel, San Francisco OneMedForum 2010 Wednesday, January 13, 2010 2:40 p.m. PT Sir...

2009-12-01 13:44:44

Ohio State University cancer researchers have developed a tumor-attacking virus that both kills brain-tumor cells and blocks the growth of new tumor blood vessels. Their research shows that viruses designed to kill cancer cells "“ oncolytic viruses "“ might be more effective against aggressive brain tumors if they also carry a gene for a protein that inhibits blood-vessel growth. The protein, called vasculostatin, is normally produced in the brain. In this study, an oncolytic...

2009-11-18 07:20:00

SAN FRANCISCO and HONG KONG, Nov. 18 /PRNewswire/ -- Jennerex, Inc., a clinical-stage biotherapeutics company developing a proprietary breakthrough class of targeted oncolytic virus therapeutics, today announced in conjunction with Lee's Pharmaceutical Holdings (HK Stock code: 8221), the execution of a collaboration and license agreement for Jennerex's lead product candidate, JX-594, in certain Asian territories. Lee's is a fully integrated pharmaceutical group with operations in...

2009-11-17 07:30:00

CALGARY, Nov. 17 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced updated results from a Phase I/II U.K. trial (REO 011) of REOLYSIN(R) combined with paclitaxel/carboplatin for patients with advanced cancers in a poster presentation at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference being held in Boston, Massachusetts. The poster presentation is entitled "Phase I/II Trial of Oncolytic Reovirus...